newsfilter
← Latest News
Business Wire·

PepGen Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

– Last patient dosed in 15 mg/kg cohort of FREEDOM-DM1; on track to report topline data from study in early Q4 2025 – – FREEDOM to conclude with the 15 mg/kg cohort based on splicing and safety data observed to date;